Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy

MONTREAL, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s responsibilities include developing Medexus’ product portfolio in both the U.S. and Canada.

The rest is here:
Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy

Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote…

-  NuGenHealth Software as a Service (SaaS) platform launch-  PVFM responds to COVID-19 with connected care solutions to serve their Medicare patient population

More here:
Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote...

RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development

Glen Rock, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment on September 15, 2020, of David Dickason as Senior Vice President Pre-clinical Product Development.

See the rest here:
RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development

Zomedica Announces Shareholder Meeting Voting Results

ANN ARBOR, Mich., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”).

See the original post here:
Zomedica Announces Shareholder Meeting Voting Results

EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO …

-- Jyseleca®  Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program --Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).1

More here:
EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO ...

Medcolcanna Organics Announces Final Approval for Listing of Common Shares on the NEO Exchange

BOGOTÁ, Colombia, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Medcolcanna Organics Inc. (“Medcolcanna”, “MCCN” or the “Company”) (TSXV: MCCN), a Canadian integrated medical cannabis company with operations in Colombia, is pleased to announce that it has received final approval to have the common shares of the Company (“Common Shares”) listed on Neo Exchange Inc. (the “NEO Exchange”). Consequently, the Company has also submitted a request to the TSX Venture Exchange (the “TSXV”) to voluntarily delist the Common Shares from the TSXV. The Company anticipates the delisting of the Common Shares from the TSXV and the subsequent listing of the Common Shares on the NEO Exchange to occur on or about the week of October 12th, 2020, subject to satisfaction of customary conditions by the NEO Exchange and the TSXV. Company Management is excited with the prospect of listing the Common Shares on the NEO Exchange and the opportunities it provides to its investors, as the Company continues the ongoing development of its business operations, including pursuing operations in the United States as integral to its business and the value that it expects to provide to its shareholders. The Company will provide further updates in future press releases surrounding the status and timing of the transfer of the listing of its Common Shares.

More here:
Medcolcanna Organics Announces Final Approval for Listing of Common Shares on the NEO Exchange

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following virtual investor conferences in October:

View original post here:
Prevail Therapeutics to Present at Upcoming Investor Conferences

Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

WARREN, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for management of seizure clusters. The FDA issues a CRL to indicate that the review cycle for an application is complete but the application cannot be approved in its current form.

Read more:
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters